



CLEODERM™ STUDY

Confirms Stability
Across Common
Dermatological APIs



John Lehman
Content Specialist

May 19, 2025

Fagron is deeply committed to research-backed innovation that elevates patient care and supports our pharmacy partners. With the rising demand for personalized dermatological treatments, compounded formulations have become essential tools for clinicians managing conditions like acne, rosacea, and hyperpigmentation.

Our latest study highlights the versatility of Cleoderm™, our cream base developed for sensitive and acne-prone skin, by evaluating the stability and compatibility of several commonly prescribed active ingredients.

Key formulations, such as adapalene with benzoyl peroxide, azelaic acid with niacinamide, and niacinamide with tretinoin, demonstrated excellent stability over a 180-day period, meeting both chemical and microbial benchmarks. Even with sensitive APIs like tretinoin and hydroquinone, the study establishes reliable beyond-use dates (BUDs), helping providers confidently dose with Cleoderm.

Want the full data and formulations on Cleoderm? Download the study below!

[Cleoderm Beyond Use Date Study](#)

For further information or questions, please feel free to reach out to us by heading to www.fagronacademy.us!